Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
US10435473B2 · kind B2 · utility
13Cited by
12References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2017 |
| Grant date | Oct 8, 2019 |
| Priority date | — |
| Expiry date | Feb 3, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.